Articles tagged with Breast Cancer
A recent study develops a physicochemical approach to optical biosensing using 1DZnO nanostructures, enabling rapid CYFRA 21-1 testing within a 5-minute detection window. The developed biosensors have the potential to provide accurate and reliable results in complex matrices like saliva.
A series of five papers highlights critical public health challenges related to cancer control in eight SAARC countries and the Rohingya refugee population in Bangladesh. The studies identify barriers contributing to significant disparities in cancer outcomes and actionable solutions to address these challenges.
A new study suggests that addressing plastic pollution could play a critical role in lowering breast cancer rates. Researchers identified nearly half of the chemicals linked to breast cancer risk as being used in plastics, including 175 potential carcinogens that should be prioritized for regulatory action.
The SONIA trial found that delaying and shortening CDK4/6 inhibitor treatment in patients with hormone receptor-positive advanced breast cancer leads to similar survival outcomes while reducing toxicity and cost by €45 million per year. This innovative approach could reduce the burden on healthcare systems worldwide.
A new study has found that tamoxifen works better for some people due to their unique gut microbiota. Researchers discovered a specific enzyme, beta-glucuronidase, in certain bacteria that helps recycle the drug into its effective form. This finding may lead to tailored treatment interventions for breast cancer patients.
A new study suggests that a cancer peer support program called Stronger Together improved psychological outcomes, as well as overall quality of life, among patients with breast and gynecological cancers in Vietnam. The program showed promise for providing critical social support in low-resource settings.
A new study from the University of Texas M. D. Anderson Cancer Center found that at least 3% of normal breast tissue cells in healthy women contain chromosome abnormalities associated with invasive breast cancer, which may guide future approaches to early detection.
Researchers found nearly all women with breast cancer-like mutations carried the anomalies in luminal cells, which line the lobules and ducts. The study suggests that these rare genetic alterations could prime or predispose these cells to cancer development.
Sylvester researchers will present over 130 studies at ASH 2024, addressing disparities in gastric cancer. Frank J. Penedo's research highlights worse outcomes for patients with unmet supportive needs, while Shria Kumar's work seeks answers for disparities in gastric cancer among specific minorities.
A novel CAR T-cell therapy targeting p95HER2-expressing cells demonstrates complete and durable antitumor responses in a subset of HER2+ tumors, raising hopes for improved cancer treatment. The therapy also activates immune cells within the tumor microenvironment, showing promising results.
A new study by Silent Spring Institute has identified multiple chemical exposures in firefighters that increase their risk of developing breast cancer. The research found 12 hazardous substances, including benzene and flame retardants, that put female firefighters at increased risk for the disease.
Researchers developed a new photoacoustic imaging technique that addresses skin tone bias in breast cancer detection. The technique, combined with specific wavelengths and beamforming methods, enhances target visibility across all skin tones, providing clearer images with improved signal-to-noise ratios.
A small clinical trial found a vaccine designed to prevent recurrence of tumors in patients with triple-negative breast cancer to be well-tolerated and stimulate the immune system. After three years, 16 out of 18 patients remained cancer-free.
Researchers developed a new AI-powered diagnostic system, FastGlioma, which reveals invisible cancerous tissue in brain tumor surgery. The technique may delay or prevent recurrence of high-grade tumors and improve patient survival.
Researchers have discovered that metabolic enzymes play a crucial role in maintaining the integrity of the human genome by orchestrating critical functions like cell division and DNA repair. This discovery could lead to new cancer therapies, particularly for triple-negative breast cancer, by exploiting its metabolic vulnerabilities.
Researchers found that a single defective copy of the BRCA1 gene can accelerate tumor growth in breast cells, contradicting the traditional two-hit model. The study suggests new possibilities for cancer prevention and therapy targeting the reprogramming effect inside cells.
A new genetic breast cancer model developed by MSU researcher could help scientists better understand why and where cancer metastasizes. The model uses a genetically engineered mouse to study the E2F5 gene's role in breast cancer development, revealing altered regulation of Cyclin D1 and tumor formation.
Researchers at Cleveland Clinic have made significant progress in their novel vaccine aimed at preventing triple-negative breast cancer. The study found that the investigational vaccine was generally well-tolerated and produced an immune response in most patients, with the highest tolerated dose to date identified.
Researchers developed a 36-gene predictive score that surpasses conventional methods in predicting tamoxifen treatment resistance. The polygenic score UAB36 has potential as a tool for personalized medicine, helping identify patients at higher risk of poor survival and suggesting alternative treatment strategies.
A new study published in The British Journal of Cancer found that whole genome sequencing can help identify treatment recommendations for cancer patients. The study evaluated the regional implementation of the 100,000 Genomes Project and found that different types of cancer were associated with varying rates of recommended actions.
A collaborative study led by Dr. Julie St-Pierre at the University of Ottawa found that promoting mitochondrial elongation in cancer cells hobbles their ability to metastasize. The research team identified a common signature that could help determine which pathways lead to decreased metastasis.
Scientists at Johns Hopkins Medicine identified 16 genes that breast cancer cells use to survive in the bloodstream, including MUC1, which is already in clinical trials. The research showed that hypoxic cells are able to migrate to higher oxygen levels and form metastasis in the body, leading to a worse prognosis.
Recent studies by MSK researchers show that the innate immune system helps maintain genome stability during DNA replication, and chronic activation can contribute to tumor development. The findings also suggest that problems with a protein complex called Mre11 can create an environment where cancer is more likely to occur.
A new study has found that Canadian women who did not identify as White have an earlier peak age of breast cancer diagnosis and higher proportions of cases diagnosed under age 50. They also experience an earlier peak age of death, with a 7-year gap in mortality rates compared to their White counterparts.
A comprehensive study analyzed diverse methods to investigate breast cancer metastases, providing new insights into their biology. The researchers found connections between clinical characteristics and malignant expression phenotypes, as well as clues about immune escape processes.
Researchers at The Jackson Laboratory have developed a new combination of imaging and computational methods to study immune cell interactions. The approach reveals that interactions between immune cells in the vicinity of breast cancer or melanoma can predict immune responses and patient outcomes.
Researchers discovered that tumor dormancy in breast cancer can be triggered by specific signaling changes within small cell clusters, called tumor emboli. Key mechanisms include reduced activity of mTOR and structural shifts in E-cadherin, which are regulated by the PI3K pathway.
Researchers at MIT have designed tiny particles that can be implanted at a tumor site, delivering heat and chemotherapy to treat cancer. The treatment approach has been shown to completely eliminate tumors in most mice and prolong their survival.
Researchers developed a method to assess which patients with metastatic triple-negative breast cancer can benefit from immunotherapy. The tool uses predictive biomarkers and machine learning-based approaches to identify patients who are likely to respond to treatment.
Researchers have identified a new therapeutic strategy to enhance the sensitivity of aggressive breast cancer cells to hormonal therapies. By inhibiting the HDAC6 protein, they were able to boost progesterone receptor levels and potentially reverse resistance to hormonal treatments.
Researchers have uncovered a mechanism by which the BRCA1 gene influences fertility, leading to genetic errors that can cause infertility. This breakthrough discovery enables potential therapeutic avenues for correcting or treating fertility issues in BRCA1 patients.
Researchers are analyzing RNA and DNA amplification in breast cancer cases to identify potential biomarkers. Funding will support the study from September 2024 to March 2025.
Non-Hispanic Black patients are more likely to receive inadequate care and experience poor survival outcomes due to delays in treatment initiation. Guideline-concordant care is crucial in improving survival rates among these patients.
A new study published in JNCCN found that Medicaid expansion was associated with longer survival rates and reduced treatment delays for patients with HR-negative, HER2-positive breast cancer. The study used data from the National Cancer Database to review results for women diagnosed with this type of breast cancer between 2010 and 2018.
Researchers have developed a 'mini-protein' that targets cancer cells expressing Nectin-4, allowing for direct delivery of radiation to tumours. The treatment shows promise in targeting multiple types of cancers and has the potential to be safe for repeated administrations.
A new study by UT Health San Antonio reveals that BRCA1 plays a crucial role in promoting error-free DNA repair through the activation of end resection enzymes. This understanding sheds light on the tumor suppressor function of BRCA1 and has important implications for breast and other cancers.
A new study from Sylvester Cancer suggests that changes in reproductive health, including earlier menarche and lower birth rates, may contribute to the higher breast cancer risk among Caribbean women. The findings highlight the importance of public health interventions targeting modifiable risk factors such as diet and exercise.
A clinical trial suggests that tucatinib and trastuzumab may benefit patients with rare bile duct cancer who also have HER2-mutated breast cancer. The treatment combination showed a 46.7% objective response rate in patients with bile duct cancer, compared to 22.2% in the broader patient group.
A clinical trial shows promise in using a gene signature to tailor chemotherapy for high-risk breast cancer patients, improving disease-free survival rates. Patients classified as low risk had significantly higher rates of disease-free and overall survival compared to those at high risk.
A clinical study published in Clinical Cancer Research confirmed that tissue stiffening in HER2-negative breast cancer can directly cause disease progression and metastasis. The use of the MeCo Score diagnostic tool was found to predict the likelihood of relapse or recurrence among patients with early-stage breast cancer.
Women who started an aerobic exercise program during chemotherapy reported improved cognitive function and quality of life compared to those receiving standard care. The study found that while cognitive performance was similar after chemotherapy completion, the exercise program had a positive impact on self-reported cognitive function.
College of Medicine – Tucson researchers are using a $3.3 million grant to test advanced breast computed tomography (CT) scans that create high-resolution 3-D images without physical compression, aiming to enhance early cancer detection and diagnosis for women with dense breasts. The technology has the potential to detect more breast c...
Immunotherapy holds promise for treating breast cancer, but its effectiveness varies. Researchers Karin de Visser, Sandra Demaria, and María Casanova-Acebes discuss advances and challenges in applying immunotherapy to this common tumor. They highlight the importance of factors like diet, biorhythms, and personalized approaches to impro...
A study analyzing Reddit posts reveals that breast cancer patients struggle with unmet emotional and financial concerns during treatment and long after. The research highlights the importance of providing adequate support and education to address these concerns.
Researchers develop physiologically relevant model to investigate breast cancer bone metastasis, holding promise for predicting risk and developing new treatments.
A Danish nationwide study found an association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and increased breast cancer risk in females ages 15 to 49. The absolute breast cancer risk is low, but the study revealed an excess risk of 14 per 10,000 females, which did not increase with duration of use.
Researchers have found that tumors with a short-lived response to hormone therapy had a mutation in the p53 gene, which can be targeted by CDK2 inhibitors. A new study also provides updated dosing guidelines for stereotactic body radiation therapy (SBRT) to minimize complications in patients with spinal metastasis.
A recent study published in Nature Cancer has discovered that cancer cells exhibit opposing pro and antitumor programs, with the former promoting metastasis and the latter combating tumor growth. This finding opens new avenues for therapeutic strategies to target highly aggressive and therapy-resistant tumors.
Research suggests that up to 42% of postmenopausal hormone-positive breast cancer cases may be linked to excess body fat, a proportion significantly higher than previously estimated using the widely used measure of BMI. The study found that a validated measure of body fat called CUN-BAE yielded more accurate results.
Researchers at Johns Hopkins Medicine developed a potential novel treatment for breast cancer bone metastasis using RK-33, which targets and inhibits the protein DDX3. The drug successfully eliminated breast cancer bone metastases in lab models by controlling cancer cell growth and proliferation.
A research team at IIT has identified a molecular signature in triple-negative breast cancer cells that can predict the formation of metastases and chemotherapy resistance. The study used single-cell sequencing to track the evolution of cancer cells over time, revealing key epigenetic features involved in tumor development.
A study by the University of the Basque Country found that YouTube videos created by medical professionals, patient associations, and individual survivors offer a wealth of knowledge and emotional support. The analysis also revealed a strong sense of community and sisterhood among viewers who share and appreciate valuable information.
Researchers at Mass General Brigham discovered that combining two therapeutic agents can selectively kill tumor cells in triple negative breast cancer, differentiating them and triggering a process similar to involution. The study provides support for clinical trials testing this new approach.
Researchers at Baylor College of Medicine have discovered DAPK3 as a key regulator of TNBC cell migration. The study found that eliminating DAPK3 protein leads to prevention of migration and invasion in laboratory experiments. Further studies are needed to assess its potential value as a therapeutic target.
A new study found that common breast cancer treatments, including chemotherapy, radiation, and surgery, can increase expression of aging markers in breast cancer survivors. The study suggests that these treatments can have a more extensive impact on the body than previously thought, leading to accelerated biological aging.
Researchers have successfully tested a new drug, trastuzumab deruxtecan, which significantly extends the lives of breast cancer patients with advanced HER2-positive disease and brain metastases. The treatment has been shown to increase survival times substantially, with over 90% of patients alive one year after treatment.
A retrospective cohort study found that AI algorithms can identify women at high risk of developing breast cancer 4-6 years before detection. The results suggest using commercial AI algorithms as a pathway to personalized screening approaches, leading to earlier cancer diagnosis.
Two UCF cancer researchers, Alicja Copik and Debbie Altomare, have received $100,000 grants from the Florida Breast Cancer Foundation to develop new treatments for breast cancer. They focus on enhancing natural killer cells to fight cancer and harnessing the body's immune system to create new therapies.
Researchers found high prevalence of frailty in breast cancer and hematopoietic cell transplant survivors, negatively impacting physical functioning and quality of life. The study supports an association between frailty and the senescence marker p16INK4a, highlighting the need for well-designed senolytic trials.
The new report finds breast cancer mortality rates overall have dropped by 44% since 1989, averting approximately 517,900 breast cancer deaths. However, the incidence of breast cancer has continued to rise, with a 1% annual increase from 2012-2021.